Company Profile

Peptimmune Inc
Profile last edited on: 5/1/2019      CAGE:       UEI:

Business Identifier: Treatments for obesity, multiple sclerosis, rheumatoid arthritis and pemphigus vulgaris
Year Founded
1996
First Award
1997
Latest Award
1997
Program Status
Inactive (Acquired)
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

64 Sydney Street Suite 380
Cambridge, MA 02139
   (617) 715-8000
   info@peptimmune.com
   www.peptimmune.com
Location: Single
Congr. District: 07
County: Middlesex

Public Profile

Founded in the mid-nineties, in July 1999, Peptimmune Inc. was acquired by Genzyme - a major player in the SBIR arena. Peptimmune Inc. had been organized around development of biopharmaceutical products that c/would arrest autoimmune disease before the could cause significant tissue damage. With a particular focus on the rare skin disease pemphigus vulgaris, Genzyme later spun-out Peptimmune in 2002. Genzyme provided initial capitalization of Peptimmune by purchasing $5.5 million in shares of preferred stock. The new company eas intended to focus on developing specific immunotherapies for treating autoimmune and allergic diseases. It is reported that in 2011, the firm was liquidated.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
500+
Revenue Range
Over 50M
VC funded?
Yes
Public/Private
Privately Held
Stock Info
----
IP Holdings
10-14

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
1997 1 NIH $99,999
Project Title: Peptimers Tm--Immunotherapy For Autoimmune Disease

Key People / Management

  Thomas P Mathers -- President

Company News

There are no news available.